What Is CJC-1295 and Why Does Vendor Quality Matter?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It was engineered to extend the half-life of GHRH by incorporating a drug affinity complex (DAC) technology that binds the peptide to albumin in the bloodstream, slowing clearance. A 2006 study published in the Journal of Clinical Endocrinology and Metabolism (Teichman et al., 28 participants) found that single and multiple injections produced sustained, dose-dependent increases in plasma growth hormone and IGF-1 levels over days rather than hours. That study is the most-cited human pharmacokinetic data on the compound.

Because CJC-1295 is a research chemical and not an approved pharmaceutical, there is no regulatory body inspecting the manufacturing facilities of vendors who sell it. The FDA does not certify research-peptide suppliers. That gap means the quality of what any vendor ships varies enormously, from pharmaceutical-grade purity to products that contain the wrong peptide entirely, degraded fragments, or bacterial endotoxins. For researchers, that variance is a scientific problem. For anyone else, it is a safety problem. Either way, the burden of verification falls entirely on the buyer.

The compound is sometimes confused with CJC-1295 without DAC, which is also called Modified GRF 1-29 or Mod GRF 1-29. These are chemically distinct peptides with different half-lives and different research profiles. A vendor that uses the names interchangeably, or that lists both under a single product page without distinguishing them, is signaling either carelessness or deliberate obfuscation. That alone is a reason to look elsewhere.

What Does a Legitimate COA Actually Look Like?

A certificate of analysis is a document issued by an independent, accredited analytical laboratory confirming what a product contains and at what purity. For peptides, the two most important tests are high-performance liquid chromatography (HPLC) and mass spectrometry (MS). HPLC measures purity as a percentage, typically reported as area-under-the-curve. A research-grade peptide should show purity at or above 98% by HPLC. Mass spectrometry confirms molecular identity by matching the measured molecular weight against the theoretical weight of the target peptide sequence. Both tests together answer two separate questions: is this pure, and is this actually CJC-1295?

The COA must be batch-specific. A vendor posting a single COA dated two years ago and applying it to every product they sell is not providing meaningful quality assurance. Legitimate vendors assign a lot or batch number to each production run, and the COA on file should match the batch number printed on the vial or listed in the order. If a vendor's website shows a COA but the batch number on the document doesn't correspond to anything you can cross-reference in your order, ask for clarification before purchasing.

Some vendors go further and include endotoxin testing (LAL test) and sterility testing in their COAs. Endotoxins are bacterial cell-wall fragments that can survive standard sterilization and cause inflammatory responses. Their presence is a manufacturing quality issue, not a purity issue, so HPLC alone won't catch them. Vendors who include endotoxin data are operating closer to pharmaceutical manufacturing standards. It's worth noting whether a vendor offers this, though its absence doesn't automatically disqualify them if the other documentation is solid.

The issuing laboratory matters. A COA from an in-house lab the vendor operates themselves is not independent verification. Look for COAs issued by third-party labs with ISO 17025 accreditation or equivalent. Some vendors name the lab on the COA; others link directly to the lab's own portal where results can be verified. Either approach is more credible than a PDF with no lab name or a lab name that returns no results in a web search.

Red Flags That Should Stop a Purchase

The most serious red flag is health or treatment claims on the product page. Phrases like 'promotes fat loss,' 'builds muscle,' 'anti-aging,' or 'improves recovery' are disease-adjacent or outcome claims that no legitimate research-chemical vendor should be making. The FDA has sent warning letters to peptide vendors for exactly this type of language. A vendor making these claims is either unaware of the regulatory line or is deliberately crossing it, and neither scenario inspires confidence in their quality controls.

Human-use administration language is a related problem. If a product page includes content written as personal instructions for using the compound in a human body, the vendor is positioning the compound for human consumption rather than laboratory research. That framing is legally problematic and practically signals that the vendor's primary customer is not a researcher. Legitimate vendors label products explicitly for research use only and do not provide personal-use guidance of any kind.

Missing or unverifiable contact information is another warning sign. A vendor with no physical address, no working phone number, and only a contact form is difficult to hold accountable if a shipment arrives damaged, mislabeled, or simply never arrives. Check whether the business has a verifiable presence: a registered company name, a real address, and a customer service channel that actually responds. Some buyers test this before purchasing by sending a pre-sale question and timing the response.

Pricing that sits far below the market average deserves scrutiny rather than celebration. Legitimate peptide synthesis at research-grade purity is not cheap. A vendor offering CJC-1295 at a fraction of competitors' prices is either cutting corners on synthesis quality, skipping third-party testing, or selling a lower-quantity vial than advertised. Compare milligram-per-dollar figures across vendors, not just sticker prices, and cross-reference against the COA purity before drawing conclusions.

Shipping, Storage, and Policy Transparency

Peptides are sensitive to heat, light, and moisture. A vendor that ships lyophilized (freeze-dried) peptides without cold packs in warm weather, or that uses packaging clearly unsuited to temperature-sensitive compounds, is not handling the product in a way that preserves the integrity documented in the COA. Some vendors ship with ice packs as standard; others offer it as an add-on. The product page or FAQ should address this directly.

Return and refund policies reveal how much confidence a vendor has in their own product. A vendor that offers no recourse for damaged shipments, wrong products, or failed third-party retesting is transferring all risk to the buyer. Look for a written policy that covers at minimum: damaged-in-transit replacements, wrong-item corrections, and a clear process for disputes. Vague language like 'we stand behind our products' without specific terms is not a policy.

Shipping disclosures matter for legal clarity. Vendors operating in the U.S. should be transparent about whether they ship internationally, what customs risks apply, and whether the product is labeled correctly for research use. A vendor that ships internationally without any disclosure about import regulations in destination countries is leaving buyers to navigate legal exposure on their own. That's not a partnership; it's a liability transfer.

Sourcing Criteria: What the Evidence Supports

The 2006 Teichman et al. trial in the Journal of Clinical Endocrinology and Metabolism remains the primary human pharmacokinetic reference for CJC-1295 with DAC. Participants in that study received doses ranging from 30 to 120 mcg/kg, and the authors reported that GH levels remained elevated for 6 days or more after a single administration. That study was industry-sponsored and involved a relatively small sample, so it represents early-phase human data rather than a definitive clinical record. Most other CJC-1295 research is preclinical, conducted in rodent models.

The evidence base for CJC-1295 is thin by pharmaceutical standards. Researchers sourcing this compound for legitimate study need material that matches the purity and identity standards of the published literature. A vendor that can't document those standards is supplying something that can't be meaningfully compared to published findings, which undermines the research value entirely.

For anyone evaluating a vendor, the sourcing criteria reduce to a short checklist: third-party COA with HPLC purity at or above 98%, mass-spec identity confirmation, batch-specific documentation, research-use-only labeling, no health or outcome claims, transparent shipping and return policies, and a verifiable business identity. Vendors who meet all of these criteria are operating at the standard the research context requires. Those who fall short on multiple points are not.